



October 2021

Harbour BioMed **Journal**
Investor Relations

02142.HK

HARBOUR
BIOMED



CONTENTS


HBM Overview	01
Company Announcement	02
Company News	03
HBM4003 phase I Data Readout	04
Interim Results Release & NDR	05
Hong Kong Biopharma Sector	06
Global Market Overview	07

HBM (02142.HK)

Overview	
Website – Investor Access	https://www.harbourbiomed.com/investor
Market Cap (09/30, Mil HK\$)	5,145
Total Share Capital (Mil)	768
Circulation Stock (Mil)	768

In September, the Hong Kong stock indexes continued to fall, following the trend of last month. The Hang Seng Index, the Hang Seng Composite Index, and the Hang Seng Healthcare Index dropped by 5.6%, 5.8%, and 2.8% respectively at the end of month. HBM's stock price fluctuated downward along with the overall market performance.

HBM Stock Performance – September



The Hang Seng Composite Index (HSCI) – September



Company Announcement

9/27 Announcement: the clinical trial of batoclimab (HBM9161) has completed the first dosing of first patient in phase III trial for the treatment of generalized myasthenia gravis (gMG).

This is a subsequent milestone to the positive phase II study outcome of the first anti-FcRn trial for the treatment of gMG. As the first anti-FcRn therapy which achieved clinical evidence in China, data received from the phase II study showed a statistically significant and clinically meaningful efficacy of batoclimab, as well as a favorable safety and tolerability profile.

9/13 Announcement: positive results from phase I study and data summary on next-generation anti-CTLA-4 antibody HBM4003.

Positive results have been announced from the phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia (the “phase I study”). The clinical data abstract has been presented at the 2021 European Society for Medical Oncology (ESMO) Congress. The data received from the phase I study, as the first clinical evidence of next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb) in solid tumors, showed favorable safety and encouraging efficacy profile of HBM4003.

9/10 Announcement: NMPA approval of two IND applications for next-generation anti-CTLA-4 antibody HBM4003.

The NMPA has approved its IND applications for HBM4003, a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with PD-1 antibody in patients with advanced hepatocellular carcinoma (HCC) and other solid tumors, as well as advanced neuroendocrine tumor/neuroendocrine carcinoma (NET/NEC) and other solid tumors.

9/20 Announcement: interim/semi-annual report.



Company News

01

Harbour BioMed announces dosing of first patient of batoclimab phase III trial in patients with generalized myasthenia gravis

02

Harbour BioMed announces approval of batoclimab phase II trial for CIDP

03

Harbour BioMed announces phase I study positive results on next-generation anti-CTLA-4 antibody HBM4003

04

Harbour BioMed announces NMPA approval of two IND applications for next-generation anti-CTLA-4 antibody HBM4003

05

National Conference on Neurology | Harbour BioMed announced batoclimab phase II study result for gMG

06

Fair for Trade in Services is here! Harbour BioMed attended the Health Services sector

07

99 Charity Day | Walk for love! Harbour BioMed helps patients with myasthenia gravis

HBM4003:

Phase I Data Readout—Encouraging Efficacy and Favorable Safety Profile

HBM4003 Positive Phase I Study Results

The innovative mechanism of depletion of regulatory T cells in tumors has been verified by preclinical and clinical data

HBM4003 showed favorable safety and tolerability

- No toxicity reported was related to lung, kidney, heart or endocrine system
- No treatment-related adverse events (TRAE) above grade 3 were found
- The maximum tolerated dose (MTD) has not been reached
 - No dose limiting toxicity (DLT) was observed at any Q3W dose level
- The most common treatment-related adverse event was diarrhea/enterocolitis


Preliminary efficacy data is encouraging for HBM4003 monotherapy

- 2 patients responded to treatment
 - One hepatocellular carcinoma (HCC) patient had confirmed partial response (PR), and the tumor reduction reached **64.4%**
 - One prostate cancer (CRPC) patient achieved a prostate surface antigen (PSA) response, and at the 6th week, the PSA was reduced by more than **50%** compared to baseline. **Target lesions reached SD for more than 26 weeks**
- 9 patients (15 patients in total) had stable disease (SD)
 - 3 patients showed tumor shrinkage

0.45 mg/kg Q3W was recommended as the phase II dose (RP2D) for dose expansion

	HBM4003 0.45mg/kg Q3W, n(%)	Ipilimumab 3mg/kg Q3W, n(%)
Number of Patient	7	111(in total)
Type of Tumor	Advanced solid tumor	Melanoma
TRAE	4(57.1)	88(79.3)
irAE	1(14.3)	68(61.3)
TRSAE	0(0.0)	19(17.1)
Treatment-related Death	0	2(1.8)

Maximum change % in total diameter of the target lesion from baseline



Interim Results Release & NDR

Interim Results Conference 08/31

Organize **10+** NDR in September
Communicate with **160+** Investors

Morgan Stanley



兴业证券
INDUSTRIAL SECURITIES



Top Financial Media Reports




Hong Kong Biopharma Sector

Market Overview

In September 2021, the HSCI closed at 3,816.0, down 5.8% from the beginning of the month. The HSHCI closed at 6,055.2, down 2.8% from the beginning of the month. The China Hong Kong Biotech index (CESHKB.CSI) closed at 12,960.2, up 1.0% from the beginning of the month.

HK Listing Biopharma Companies (18A)



Global Market Overview

Global Market Index			
	Closing Price		
	2021.09.01	2021.09.15	2021.09.30
Dow Jones Industrial	35,312.5	34,814.4	33,843.2
Nasdaq Composite	15,309.4	15,161.5	14,448.6
UK FTSE 100	7,149.9	7,016.5	7,086.4
German DAX	15,824.3	15,616.0	15,260.7
France CAC40	6,759.7	6,583.6	6,520.0

HK Market Index			
	Closing Price		
	2021.09.01	2021.09.15	2021.09.30
Hang Seng Index	26,028.3	25,033.2	24,575.4
Hang Seng Composite Index	4,050.5	3,898.1	3,816.0
Hang Seng Tech Index	6,693.7	6,298.1	6,101.5
HS China Enterprise Index	9,271.3	8,936.3	8,726.4
Hang Seng Healthcare Index	6,229.4	6,068.1	6,055.2

Major Global Economic Indicators – September			
Country	Related Indicator	Estimated	Actual
US	Number of Unemployment Benefits Initial Claiming for the week of 9/25 (thousand people)	33.5	35.1
US	The Index of Consumer Sentiment of the University of Michigan	67.1	77.1
Eurozone	Sentix Investor Confidence	19.7	19.6
Germany	ZEW Economic Sentiment	30.3	26.5
Germany	Gfk Consumer Confidence	-8.0	-13.0

- According to a Citigroup Inc. survey of clients, a majority of investors harbor fears of persistently high inflation, with a 20% pullback in stocks seen as more likely than a 20% rally
- US treasury multi-term yields increased. As of September 28, 10-year yield touched 1.5%, highest since June
- FOMC and Chicago Fed President Evans expected the Fed will begin to reduce its bond purchase program, and it will be 2023 before an interest rate hike is warranted

HARBOUR BIOMED



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice[®] generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE[™]) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice[®] with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

ir@harbourbiomed.com
www.harbourbiomed.com

linkedin:
<https://www.linkedin.com/company/13244036/admin/>